Your browser is no longer supported. Please, upgrade your browser.
Settings
CRXT [NASD]
Clarus Therapeutics Holdings, Inc.
Index- P/E9.93 EPS (ttm)0.46 Insider Own41.90% Shs Outstand7.25M Perf Week-12.45%
Market Cap96.70M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-31.89%
Income3.30M PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-54.98%
Sales9.76M P/S9.91 EPS this Y- Inst Trans287.77% Short Ratio0.23 Perf Half Y-54.93%
Book/sh6.68 P/B0.68 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh0.01 P/C483.51 EPS next 5Y- ROE- 52W Range3.43 - 31.24 Perf YTD-55.11%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.37% Beta-
Dividend %- Quick Ratio0.30 Sales past 5Y- Gross Margin- 52W Low33.24% ATR0.73
Employees- Current Ratio0.30 Sales Q/Q238.10% Oper. Margin- RSI (14)39.32 Volatility9.32% 14.17%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.33 Prev Close4.93
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.46M Price4.57
Recom- SMA20-4.58% SMA50-36.29% SMA200-50.42% Volume476,729 Change-7.30%
Oct-14-21 09:05AM  
Sep-26-21 07:55PM  
Sep-22-21 09:05AM  
Sep-16-21 09:05AM  
Sep-15-21 09:05AM  
Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.